Soteria Biotherapeutics is a technology company.
Soteria Biotherapeutics has raised $42.0M across 1 funding round.
Key people at Soteria Biotherapeutics.
Soteria Biotherapeutics has raised $42.0M in total across 1 funding round.
Key people at Soteria Biotherapeutics.
Soteria Biotherapeutics has raised $42.0M in total across 1 funding round.
Soteria Biotherapeutics's investors include Aglaia BioMedical Ventures, Keno Gutierrez, BGV (BioGeneration Ventures), Forbion, Westlake Village BioPartners.
Soteria Biotherapeutics is an immuno-oncology company developing next-generation bispecific T-cell engagers for solid tumor cancers using its proprietary T-LITE platform, which enables switchable activation for safer, more controllable therapies with reduced side effects.[1][2] The platform targets healthcare providers and cancer patients by leveraging the immune system to combat tumors more effectively than traditional bispecifics, addressing limitations like cytokine release syndrome.[1][2] Founded in 2018 and based in the San Francisco Bay Area (with addresses in San Francisco and San Mateo, California), it raised $42 million in Series A funding in 2021 led by Roche Venture Fund and 5AM Ventures, signaling strong early momentum in biotech.[2][4]
Soteria Biotherapeutics emerged in 2018 from innovations in controllable immunotherapy, focusing on bispecific T-cell engagers that activate only in the presence of a small-molecule switch, minimizing off-tumor toxicity.[1][2][4] While specific founders are not detailed in available sources, the company's launch was marked by a $42 million Series A round led by Roche Venture Fund and 5AM Ventures, highlighting immediate validation from top biotech investors.[2][4] Early traction came from the T-LITE platform's promise for solid tumors, where standard T-cell engagers struggle due to safety issues, positioning Soteria as a pioneer in "switchable" therapies.[1][4]
(Note: A separate Taiwan-based entity, Soteria Biotech Co., Ltd., develops unrelated medical software for respiratory diseases like OSAS, but this profile focuses on the U.S. immuno-oncology firm matching the query's technology context.[3])
Soteria rides the bispecific T-cell engager wave in immuno-oncology, a market exploding due to successes like Blincyto but hampered by toxicity in solid tumors—where Soteria's controllable platform fills a critical gap.[1][2] Timing aligns with surging demand for precision cancer therapies amid advances in antibody engineering and oral small-molecule combos, fueled by Big Pharma interest (e.g., Roche's lead investment).[4] Market forces like rising solid tumor incidence and regulatory push for safer CAR-T alternatives favor Soteria, influencing the ecosystem by pioneering "titratable" immunotherapies that could expand T-cell engager use beyond hematology.[1][2]
Soteria's T-LITE platform positions it for IND filings and Phase 1 trials in solid tumors, potentially yielding first-in-class data by 2026-2027 if preclinical promise holds.[1][2][4] Trends like combo therapies with PD-1 inhibitors and AI-optimized switches will shape its path, amplifying influence as Roche's network accelerates partnerships or acquisition.[4] As controllable immunotherapies mature, Soteria could redefine solid tumor treatment standards, building on its $42M launch to drive broader adoption of switchable biologics—echoing its mission to harness immunity safely from day one.[2][4]
Soteria Biotherapeutics has raised $42.0M across 1 funding round. Most recently, it raised $42.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $42.0M Series A | Aglaia BioMedical Ventures, Keno Gutierrez, BGV (BioGeneration Ventures), Forbion, Westlake Village BioPartners |
